List of Studies ( Metabolite:PC P-36:5 or PC O-36:6)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004133 | AN006851 | Metabolite profiling of portal and cardiac puncture plasma in C57Bl6 mice treated with Vancomycin or Metronidazole under a regular or high fat diet. | Blood | Mouse | Diabetes | Broad Institute of MIT and Harvard | LC-MS |
| ST004093 | AN006783 | Autoimmune Disease Risk Gene ANKRD55 Promotes T Cell Proliferation and Th17 2 Effector Function Through Metabolic Modulation | T-cells | Mouse | Autoimmune disease | Broad Institute of MIT and Harvard | LC-MS |
| ST003514 | AN005769 | Highly reliable LC-MS lipidomics database for efficient human plasma profiling based on NIST SRM 1950 | Blood | Human | Universidad CEU San Pablo | LC-MS | |
| ST003438 | AN005649 | Unbiased genetic screening and metabolomics identifies glial adenosine metabolism as a therapeutic target in Parkinson’s disease | Fly Head | Fruit fly | Parkinsons disease | Broad Institute of MIT and Harvard | LC-MS |
| ST003103 | AN005077 | Reinforcing the Evidence of Mitochondrial Dysfunction in Long COVID Patients using a Multiplatform Mass Spectrometry-based Metabolomics Approach | Blood | Human | COVID-19 | Universidad CEU San Pablo | GC-MS/LC-MS |
| ST002903 | AN004764 | Identification and targeting of microbial putrescine acetylation in bloodstream infections | Blood | Human | Septic shock | Broad Institute of MIT and Harvard | LC-MS |
| ST002817 | AN004584 | Investigation of metabolism in hypertrophic cardiomyopathy - Lipidomics | Heart | Mouse | Cardiomyopathy | University of California, San Francisco | LC-MS |
| ST002764 | AN004499 | Identification of pre-diagnostic lipid sets associated with liver cancer risk using untargeted lipidomics and chemical set analysis – a nested case-control study within the ATBC cohort | Blood | Human | Cancer | Icahn School of Medicine at Mount Sinai | LC-MS |
| ST002700 | AN004376 | Metabolomic analysis of maternal mid-gestation plasma and cord blood: lipidomics | Blood | Human | Autism | Columbia University | LC-MS |
| ST002536 | AN004173 | Effectors enabling adaptation to mitochondrial complex I loss in Hürthle cell carcinoma | Thyroid | Human | Cancer | Broad Institute of MIT and Harvard | LC-MS |
| ST002002 | AN003265 | A case-control study on plasma metabolomics analysis in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (Part 3) | Blood | Human | Myalgic encephalomyelitis/chronic fatigue syndrome | Columbia University | LC-MS |
| ST001949 | AN003173 | Plasma Metabolome Normalization in Rheumatoid Arthritis following initiation of Methotrexate and the Identification of Metabolic Biomarkers of Efficacy | Blood | Human | Rheumatoid arthritis | University of Kansas | GC-MS |
| ST001942 | AN003185 | Lipidomics of esophageal adenocarcinoma | Esophagus | Human | Cancer | QIMR Berghofer Medical Research Institute | LC-MS |
| ST001888 | AN003059 | A Metabolome Atlas of the Aging Mouse Brain (Study part II) | Brain | Mouse | University of California, Davis | GC-MS/LC-MS | |
| ST001843 | AN002986 | Identification of unique metabolite networks between Latino and Caucasian patients with nonalcoholic fatty liver disease (NAFLD) (part II) | Blood | Human | Fatty liver disease | University of California, Davis | GC-MS |
| ST001843 | AN002986 | Identification of unique metabolite networks between Latino and Caucasian patients with nonalcoholic fatty liver disease (NAFLD) (part II) | Liver | Human | Fatty liver disease | University of California, Davis | GC-MS |
| ST001815 | AN002946 | Metabolic Markers of Methotrexate Response in Juvenile Idiopathic Arthritis | Blood | Human | Arthritis | University of Kansas | GC-MS/LC-MS |
| ST001637 | AN002677 | A Metabolome Atlas of the Aging Mouse Brain | Brain | Mouse | University of California, Davis | GC-MS/LC-MS | |
| ST001246 | AN002070 | TFPa/HADHA is required for fatty acid beta-oxidation and cardiolipin re-modeling in human cardiomyocytes (part-I) | Cultured cells | Human | Sudden infant death syndrome | University of California, Davis | LC-MS |
| ST001211 | AN002018 | Metabolomic Markers of Methotrexate Response, In Vitro | Cultured cells | Human | University of Kansas | GC-MS/LC-MS | |
| ST001063 | AN001739 | Lipidomics analysis for aged mice organs | Adipose tissue | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001063 | AN001739 | Lipidomics analysis for aged mice organs | Brain | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001063 | AN001739 | Lipidomics analysis for aged mice organs | Liver | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001063 | AN001739 | Lipidomics analysis for aged mice organs | Muscle | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001000 | AN001881 | Gut microbiome structure and metabolic activity in inflammatory bowel disease | Feces | Human | Broad Institute of MIT and Harvard | LC-MS | |
| ST000991 | AN001617 | Validating Quantitative Untargeted Lipidomics Across Nine Liquid Chromatography−High-Resolution Mass Spectrometry Platforms (part IX) | Blood | Human | University of California, Davis | LC-MS | |
| ST000990 | AN001616 | Validating Quantitative Untargeted Lipidomics Across Nine Liquid Chromatography−High-Resolution Mass Spectrometry Platforms (part VIII) | Blood | Human | University of California, Davis | LC-MS | |
| ST000989 | AN001615 | Validating Quantitative Untargeted Lipidomics Across Nine Liquid Chromatography−High-Resolution Mass Spectrometry Platforms (part VII) | Blood | Human | University of California, Davis | LC-MS | |
| ST000988 | AN001614 | Validating Quantitative Untargeted Lipidomics Across Nine Liquid Chromatography−High-Resolution Mass Spectrometry Platforms (part VI) | Blood | Human | University of California, Davis | LC-MS | |
| ST000987 | AN001613 | Validating Quantitative Untargeted Lipidomics Across Nine Liquid Chromatography−High-Resolution Mass Spectrometry Platforms (part V) | Blood | Human | University of California, Davis | LC-MS | |
| ST000986 | AN001612 | Validating Quantitative Untargeted Lipidomics Across Nine Liquid Chromatography−High-Resolution Mass Spectrometry Platforms (part IV) | Blood | Human | University of California, Davis | LC-MS | |
| ST000985 | AN001611 | Validating Quantitative Untargeted Lipidomics Across Nine Liquid Chromatography−High-Resolution Mass Spectrometry Platforms (part III) | Blood | Human | University of California, Davis | LC-MS | |
| ST000984 | AN001610 | Validating Quantitative Untargeted Lipidomics Across Nine Liquid Chromatography−High-Resolution Mass Spectrometry Platforms (part II) | Blood | Human | University of California, Davis | LC-MS | |
| ST000983 | AN001609 | Validating Quantitative Untargeted Lipidomics Across Nine Liquid Chromatography−High-Resolution Mass Spectrometry Platforms (Part I) | Blood | Human | University of California, Davis | LC-MS | |
| ST000879 | AN001432 | Diet, genetics and gut microbiome drive dynamic changes in plasma metabolites [plasma] | Blood | Mouse | Broad Institute of MIT and Harvard | LC-MS |
